Status: retired, Primitive. Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3303488010 | Oropharyngeal form buprenorphine + naloxone (product) | en | Fully specified name | Inactive | Initial character case insensitive | SNOMED CT core |
| 3303490011 | Oropharyngeal form buprenorphine + naloxone | en | Synonym | Inactive | Initial character case insensitive | SNOMED CT core |
| 3488802019 | Product containing buprenorphine and naloxone in oropharyngeal dosage form (medicinal product form) | en | Fully specified name | Inactive | Case insensitive | SNOMED CT core |
| 3498092011 | Buprenorphine and naloxone in oropharyngeal dosage form | en | Synonym | Inactive | Case insensitive | SNOMED CT core |
| 3498093018 | Product containing buprenorphine and naloxone in oropharyngeal dosage form | en | Synonym | Inactive | Case insensitive | SNOMED CT core |
| 3708878012 | Buprenorphine- and naloxone-containing product in oropharyngeal dose form | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 3708879016 | Product containing buprenorphine and naloxone in oropharyngeal dose form (medicinal product form) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Is a | Buprenorphine- and naloxone-containing product in oromucosal dose form | false | Inferred relationship | Some | ||
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Is a | Product manufactured as oropharyngeal dose form | false | Inferred relationship | Some | ||
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Has active ingredient | Naloxone | false | Inferred relationship | Some | 1 | |
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Has active ingredient | Buprenorphine | false | Inferred relationship | Some | 2 | |
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Has manufactured dose form | Oromucosal AND/OR gingival dosage form | false | Inferred relationship | Some | ||
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Is a | Buprenorphine- and naloxone-containing product | false | Inferred relationship | Some | ||
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Is a | Buprenorphine-containing product in oropharyngeal dose form | false | Inferred relationship | Some | ||
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Is a | Naloxone-containing product in oropharyngeal dose form | false | Inferred relationship | Some | ||
| Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Has manufactured dose form | Oropharyngeal dose form | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Buprenorphine hydrochloride 2mg + naloxone hydrochloride 0.5mg sublingual tablet | Is a | False | Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Inferred relationship | Some | |
| Buprenorphine hydrochloride 8mg + naloxone hydrochloride 2mg sublingual tablet | Is a | False | Buprenorphine- and naloxone-containing product in oropharyngeal dose form | Inferred relationship | Some |
Reference Sets
Concept inactivation indicator reference set
REPLACED BY association reference set